In yesterday’s Wall Street session, Adc Therapeutics SA (NYSE:ADCT) shares traded at $3.13, up 63.02% from the previous session.
ADCT stock price is now 12.80% away from the 50-day moving average and -10.39% away from the 200-day moving average. The market capitalization of the company currently stands at $493.37M.
With the price target of $6, Stephens recently initiated with Overweight rating for Adc Therapeutics SA (NYSE: ADCT). , while ‘Guggenheim’ rates the stock as ‘Buy’
In other news, Redmile Group, LLC, 10% Owner sold 25,352 shares of the company’s stock on Dec 04 ’24. The stock was sold for $52,479 at an average price of $2.07. Upon completion of the transaction, the 10% Owner now directly owns 15,566,731 shares in the company, valued at $48.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01 ’24, 10% Owner Redmile Group, LLC bought 400,000 shares of the business’s stock. A total of $1,124,000 was incurred on buying the stock at an average price of $2.81. This leaves the insider owning 15,669,217 shares of the company worth $49.04 million. A total of 19.50% of the company’s stock is owned by insiders.
During the past 12 months, Adc Therapeutics SA has had a low of $0.94 and a high of $6.04. The fifty day moving average price for ADCT is $2.7748 and a two-hundred day moving average price translates $3.49275 for the stock.
The latest earnings results from Adc Therapeutics SA (NYSE: ADCT) was released for 2024-09-30. The net profit margin was -300.00% and return on equity was -705.53% for ADCT. The company reported revenue of $18.46 million for the quarter, compared to $14.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 27.4 percent.
